News >

AML Field Advances With New Agents, But More Work Remains

Gina Columbus @ginacolumbusonc
Published: Tuesday, Dec 05, 2017

Olga Frankfurt, MD

Olga Frankfurt, MD
The year 2017 saw 4 regulatory approvals in the field of acute myeloid leukemia (AML) that have made significant improvements in patient outcomes.

on Hematologic Malignancies, Frankfurt, an associate professor of medicine at the Feinberg School of Medicine, Northwestern University, discussed advances in the field of AML and challenges that lie ahead.

OncLive: We have seen much progress in the field of AML this past year. Can you highlight some of the advancements?

Frankfurt: There have been 4 drugs that have received FDA approval, which includes midostaurin, a FLT3-targeted therapy given in combination with chemotherapy. This is obviously for FLT3-expressed patients who express FLT3 mutations.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication